Seasonality of asthma exacerbations: efficacy of fluticasone furoate/vilanterol 100/25µg (FF/VI) vs fluticasone furoate 100µg (FF) alone

@inproceedings{Crim2017SeasonalityOA,
  title={Seasonality of asthma exacerbations: efficacy of fluticasone furoate/vilanterol 100/25µg (FF/VI) vs fluticasone furoate 100µg (FF) alone},
  author={Courtney C Crim and Lucy Frith and Pinal J. Patel},
  year={2017}
}
  • Courtney C Crim, Lucy Frith, Pinal J. Patel
  • Published 2017
  • Medicine
  • Aim: Study HZA106837 demonstrated a reduced risk of asthma exacerbations with FF/VI vs FF, measured by time-to-first severe asthma exacerbation over a ≥24–78 week treatment period (Bateman et al; Thorax 2014). This post-hoc analysis investigated whether asthma exacerbation prevalence varied across seasons. Methods: Patients aged ≥12 years with asthma for ≥1 year, receiving an ICS or ICS/LABA and with ≥1 exacerbation requiring systemic corticosteroids and/or hospital visit in the previous year… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    Topics from this paper.